Depending on the combined positive score (CPS) that reflects PD-L1 expression on tumor cells, infiltrating lymphocytes and macrophages, overall survival (OS) was significantly prolonged in patients receiving pembrolizumab compared to those receiving cetuximab–chemotherapy: PD-L1 CPS ≥ 20 and CPS ≥ 1, respectively. This evidence concerns the gene CD274 and neoplasm.